The 10 most recent market catalysts affecting $AEMD, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Bullish
Impact 95
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
Aethlon Medical's stock experienced a massive 374.13% surge due to its announced all-stock merger with North Immunology Inc., a biotech firm. This merger, backed by a significant $…
Sep 17, 2026
Macro/Central Bank
Bullish
Impact 65
Crude Oil Down 1%; US Pending Home Sales Rise 0.3% In August
The filing indicates a generally positive day for US equities, with the S&P 500 gaining 1%. This was supported by strong performance in information technology shares. However, the …
Sep 17, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Thursday's Intraday Session
This 'filing' is actually a Benzinga news report summarizing intraday stock performance, not an official SEC 8-K. It details the top gainers and losers in the healthcare sector for…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 95
Aethlon Medical Pivots to Biotechnology with All-Stock Merger
Aethlon Medical (AEMD) is effectively being acquired by North Immunology through an all-stock reverse merger, with Aethlon shareholders retaining only 4.75% of the combined entity.…
Sep 17, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Thursday's Pre-Market Session
This filing highlights pre-market trading activity for several health care stocks, showing both significant gainers and losers. The extreme volatility, particularly for Aethlon Med…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Aethlon Medical shares are trading higher after the company announced that it has entered into a definitive merger agreement for an all-stock transaction with North Immunology.
This headline signifies a significant corporate catalyst for Aethlon Medical, driving its stock higher due to the definitive merger agreement. All-stock transactions often lead to …
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 95
Aethlon Medical To Merge With North Immunology; AEMD Holders To Retain ~4.75% Of Combined Company, With North Immunology Stockholders To Own ~95.25%; NewCo Expected To Have Pro Forma Equity Value Of ~$346.5M; Oversubscribed $180M Private Placement Expected To Fund NewCo Operations Into H2 2028
Aethlon Medical (AEMD) is undergoing a reverse merger with North Immunology, a privately held biotechnology company. This is a transformative event for AEMD, as existing shareholde…
Sep 3, 2026
Corporate Catalyst
Neutral
Impact 60
Aethlon Medical Has Received A Notice Of Allowance For A U.S. Patent Titled "DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF".
Aethlon Medical (AEMD) has secured a Notice of Allowance for a U.S. patent covering devices and methods for treating viral infections. This is a positive development as it indicate…
Jul 13, 2026
Corporate Catalyst
Neutral
Impact 55
Patients In Aethlon Medical's Second Cohort Of Its Australian Oncology Feasibility Study Demonstrated Biological Changes
Aethlon Medical (AEMD) reported that the second cohort of its Australian oncology feasibility study showed biological changes consistent with previously reported observations. This…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.